About Exact Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company’s pipeline products focus on enhancing the Cologuard test’s performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Address: 5505 Endeavor Lane, Madison, WI, United States, 53719
Exact Sciences Corporation News and around…
Latest news about Exact Sciences Corporation (EXAS) common stock and company :
In this article, we will take a look at the 11 best genomic stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Genomic Stocks to Buy Now. Genomics is a branch of biology that studies the structure, function, evolution, mapping, and editing of genomes, […]
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in PetMed Express Inc (PETS), where a total of 1,542 contracts have traded so far, representing approximately 154,200 underlying shares. That amounts to about 44.4% of PETS's average daily trading volume over the past month of 347,220 shares..
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its third quarter 2021 financial results after the close of the U.S. financial markets on November 2, 2021. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Investors in EXACT Sciences Corp. (EXAS) saw new options become available today, for the November 26th expiration..
Investors in EXACT Sciences Corp. (EXAS) saw new options become available this week, for the November 19th expiration..
Investors in EXACT Sciences Corp. (EXAS) saw new options begin trading this week, for the April 2022 expiration..
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— Russell 1000 Momentum Focus ETF (ONEO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $112.24 per unit.
The pandemic isn't over yet.
The company’s best customers are likely to step up their spending. Also, Wall Street views on Electronic Arts, Exact Sciences, Albireo Pharma, Regions Financial, and Papa John’s International.
Columbia Large Cap Growth Fund invests only in its managers' best ideas. That strategy has made it one of the best mutual funds.
Exact Sciences(NASDAQ:EXAS)shares are trading higher after the company announced an expansion of its primary care sales team ...
Shares of Exact Sciences Corp. rallied 8.0% in afternoon trading Wednesday, after the molecular diagnostics company said it taking over the selling of its Cologuard at-home colon cancer screening test from Pfizer Inc. , and said it was discussing with Pfizer "material changes" to their promotion agreement. The company said it learned in late August that Pfizer cut the sales positions supporting its business tasked with selling Cologuard, so Exact offered those displaced sales representatives job
History says this month can be scary. These stocks can get you through it.
Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves ...
Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.
Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic
Feds tell judge that the combined companies will unfairly monopolize the market for blood screening that can detect multiple cancers.
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
With excellent prospects, these three companies are built to last and today's prices are attractive.
Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX Breast Recurrence Score® Program. The test helps guide chemotherapy treatment recommendations and provides risk of distant recurrence in patients with hormone receptor-positive, HER2-negative early-stage breast cancer with up to three positive lymph nodes. MHLW approval is a critical step in making Oncotype DX® accessible to breast cancer patients in Japan.
Exact Sciences (NASDAQ:EXAS) shares experienced unusual options activity on Friday. The stock price moved down to $93.95 following the ...
Exact Sciences Corp. (Nasdaq: EXAS) announced today that the performance of its Oncoguard™ Liver liquid biopsy test is now published online in the peer-reviewed journal Clinical Gastroenterology and Hepatology (CGH). The test delivers 82% early-stage sensitivity, and an overall 88% sensitivity and 87% specificity1 for the detection of hepatocellular carcinoma (HCC), the leading form of liver cancer.
RiverPark Funds, an investment management firm, published its “RiverPark Large Growth Fund” second quarter 2021 investor letter – a copy of which can be downloaded here. The RiverPark Large Growth Fund (the “Fund”) returned 13.1% for the second quarter of 2021, while its benchmarks, the S&P 500 Total Return Index (“S&P”) advanced 8.5%, the Russell […]
In this article, we discuss the 10 Reddit’s WallStreetBets stocks that are tumbling. If you want to skip our detailed analysis of these stocks, go directly to the 5 Reddit’s WallStreetBets Stocks That are Tumbling. Social media has been exerting an ever-greater influence on the movement of markets over the past few months. The mainstream […]
The market rally is at highs, but tricky to navigate. Apple, Tesla and Square are near buy points. BioNTech earnings loom.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The haters have come out against portfolio manager Cathie Wood. In fact, an ETF is preparing to launch that bets against her stocks to buy. The post 10 Stocks to Buy From Cathie Wood’s Fleet of ETFs appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Illumina will likely be allowed to buy Grail. But even without that deal, ILMN stock is very attractive, given the company's strong growth drivers. The post Illumina Stock Will Be Unstoppable Once the Grail Acquisition Gets Approved appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..